ARDS - Aridis Pharmaceuticals Inc Stock Price, Fair Value and News

Market Closed

ARDS Stock Valuation Analysis

Valuation

Max Portfolio %

ARDS Price Action

ARDS RSI Chart

ARDS Stock Valuation Analysis

Valuation

Max Portfolio %

ARDS Valuation

ARDS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARDS Fundamentals

ARDS Revenue

ARDS Earnings

ARDS Profitability

ARDS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.0M	21.4M	21.5M	0
2022	4.4M	4.6M	1.9M	0
2021	0	2.0M	3.1M	4.1M
2020	0	1.0M	1.0M	1.0M
2019	3.5M	3.4M	2.4M	1.0M
2018	1.3M	1.8M	2.3M	2.8M
2017	0	0	0	860.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

CEO	Dr. Vu L. Truong Ph.D.
WEBSITE	aridispharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	37